Blog: Patient Insights & Thought Leadership

Healthcare Industry Thought Leadership

Health Union’s data-driven industry conversations help pharma make smarter, more effective decisions.
Check out our latest thought leadership pieces below.

Differences in DMT treatment experiences among people with MS: Here’s what patients say

July 30, 2018

For many people living with multiple sclerosis (MS), treatment decisions can often be nuanced and complicated. In April of 2018, the American Academy of Neurology (AAN) released new guidelines about when to begin, change, and end disease-modifying therapies (DMTs) for MS patients. MS In America 2018 results may help the healthcare industry gain a broader understanding of people’s experiences, or lack thereof, with DMTs and other MS treatment options.

WHITEPAPER DOWNLOAD: #authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities

June 28, 2018

Download the full free whitepaper, "#authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities"

Expanding Patient Voices and Understanding Their Perspectives

Patient Centricity Starts With Patients: Closing the Trial Recruitment Gap

June 27, 2018

There is a lot of talk in the industry about patient centricity, but is it the reality? We talk about putting the needs of patients first and keeping them central in the business decisions we make across the healthcare industry. However, as we discussed on a panel at this year’s DIA 2018 Global Annual Meeting, somehow in the effort to amplify patient centricity, a critical voice is often underrepresented—the voice of the patient.

Building Relationships vs. Publishing Content: Reflecting on the Renewed Interest In Migraine Disease

June 1, 2018

A new class of migraine drugs, called anti-CGRPs (calcitonin gene-related peptide) are expected to reinvigorate a market that has been largely dormant for some time. Four biopharma companies, Amgen, Teva, Lilly and Alder are entering the fray. Not surprisingly, the intense competition and pharma investment associated with this market dynamic has led traditional “eyeball driven” publishers, like WebMD, Everyday Health and others on a quest to offer substantially more migraine-related content in reaction to this market opportunity.

Healthcare Industry Thought Leadership

Differences in DMT treatment experiences among people with MS: Here’s what patients say

WHITEPAPER DOWNLOAD: #authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities

Patient Centricity Starts With Patients: Closing the Trial Recruitment Gap

Building Relationships vs. Publishing Content: Reflecting on the Renewed Interest In Migraine Disease

The Future of HCP Engagement: Health Union’s Rx for Healthcare’s Information Overload

Case Study: Unlocking Unrivaled Programmatic Performance in Pharmaceutical Advertising

From Qualified to Converted: Why Your Next Campaign Needs to Focus on Low-Funnel Audiences

The Pharma Paradox: Balancing Authenticity and Safety in Influencer Marketing

Contact